About Bristol-Myers Squibb Co
- Industry: Pharmaceuticals
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.bms.com
Frequently Asked Questions
What is the 52-week range for BMY?
The 52-week high is $68.64 and the 52-week low is $42.52.
What is the P/E ratio for BMY?
The Price to Earnings (P/E) ratio is 13.46.
What is the dividend yield for BMY?
The indicated annual dividend yield is 4.58%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 46.76%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 18.87%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.94.
Analyst Recommendation Trends
Wall Street analyst consensus for BMY over the last few months:
Latest BMY News
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something new, before the revenue disappeared. AbbVie is widely seen as having pulled it off and […]
Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns
BMY passes ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but payout sustainability and falling EPS warrant income-investor caution.
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
How Has Pfizer's Story Changed?
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
5 High-Yield Dividends With Ex-Dates Days Away: Buy Before the Window Closes
Four dividend stocks from Philip Morris to JPMorgan Chase have ex-dates landing within days, and missing the cutoff means the payout goes to the seller. The clock is already running.
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
PRINCETON, N.J., October 01, 2026--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
PRINCETON, N.J., September 30, 2026--U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients
This Pharma Giant Has The Right Medicine For Income Investors
Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb.
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame.
FORTUNE ANNOUNCES ADDITIONAL POWERHOUSE SPEAKERS AND SPONSORS AT FORTUNE 500 INNOVATION FORUM, NOV. 16-17 IN DETROIT
Fortune today announced an additional group of speakers for the Fortune 500 Innovation Forum, November 16–17, 2026, in Detroit, Michigan. The newly confirmed leaders will join CEOs, entrepreneurs, policymakers, investors, and civic innovators from across the country for conversations about the forces reshaping American business, technology, work, manufacturing, and prosperity.
Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.
PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer
Key TakeawaysPfizer yields about 6% and Bristol Myers about 4%, and each has more than $22 billion of revenue from drugs losing U. S.
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.
FDA Approves Bristol Myers Squibb's Camzyos As First Treatment For Children With Obstructive Hypertrophic Cardiomyopathy Weighing At Least 30 kg
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-improve-functional-capacity-and-symptoms-children-rare-inherited-heart
What Is Merck Stock's Biggest Opportunity?
Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. Click for this updated look at LXRX.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026
How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors
In September 2026, Bristol Myers Squibb reported first-time, pivotal Phase 3 EXCALIBER-RRMM data showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone produced a statistically significant, clinically meaningful improvement in minimal residual disease–negative complete responses versus a standard daratumumab-based regimen in relapsed or refractory multiple myeloma. This MRD-focused outcome is particularly important because it informs the accelerated approval pathway for ZENBEXUS...
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.
Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial
Bristol-Myers Squibb (NYSE:BMY) reported pivotal Phase 3 EXCALIBER-RRMM data for ZENBEXUS in relapsed or refractory multiple myeloma. The Phase 3 trial showed a clinically meaningful advantage in MRD-negative complete response rates versus standard therapy. The first full readout of EXCALIBER-RRMM highlights potential clinical and commercial relevance for ZENBEXUS in a crowded myeloma treatment field. The MRD-negative complete response results from EXCALIBER-RRMM are important, but investors...
Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now
Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 126%
The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.
AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers
Bristol-Myers Squibb has delivered a 51.6% gain over the past year, helped by fresh drug data and a steadily expanding pipeline, which puts fresh focus on what investors are really paying for its future cash flows today. With the stock recently closing at US$63.88, the key issue is whether that price still lines up with what the company’s current and prospective cash generation can support. Bristol-Myers Squibb’s 51.6% one year return puts meaningful expectations into the share price, so the...
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation
With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.
1 Cash-Producing Stock to Keep an Eye On and 2 Facing Challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.
Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook?
On September 25, Bristol-Myers Squibb Company (NYSE:BMY) announced milestone results from its Phase 3 EXCALIBER-RRMM trial evaluating Zenbexus in combination with daratumumab and dexamethasone (ZDd) for relapsed or refractory multiple myeloma. At a median follow-up of 15.7 months across 420 patients, ZDd demonstrated a statistically significant improvement in minimal residual disease (MRD)-negative complete response rates […]
Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue?
On September 8, Bristol-Myers Squibb Company (NYSE:BMY) announced positive Phase 2 results from its registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall response rate (ORR) alongside strong complete response rates […]
What Are Merck Stock Investors Overlooking?
If you own Merck (MRK) stock, the number to watch is the sales of one cancer drug family. KEYTRUDA family sales were $8.4 billion in the second quarter of 2026. That was about half of Merck's $16.6 billion in quarterly revenue. Management now expects KEYTRUDA’s U.S. growth to moderate, raising questions about whether the stock's recent run has fully priced in the transition.
Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Originally published by the Bristol Myers Squibb FoundationNORTHAMPTON, MA / ACCESS Newswire / September 28, 2026 / Francis Kwoba is a 68-year-old retired policeman from Bungoma County, Kenya. During one of his usual morning runs, he experienced a sudden sharp pain in his chest.
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability. Speaking at the 2026 TD Cowen Neuropsychiat
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.
Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs
Long-term bond yields persist, but investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks. Click for more.
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]
Dividend Champion, Contender, And Challenger Highlights: Week September 27
Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J., September 25, 2026--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Key Stats for Acadia Pharmaceuticals StockToday’s Performance: -19%52-Week Range: $20 to $31Valuation Model Target Price: $34Implied Upside: 54%What Happened?Acadia Pharmaceuticals stock (NASDAQ: ACAD) is facing a major test over whether remlifanserin still has a credible path forward in Alzheimer’s disease psychosis after its Phase 2 trial narrowly missed its main goal. Remlifanserin is being developed to treat hallucinations and delusions associated with Alzheimer’s disease psychosis, an indic
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
Bristol-Myers Squibb (NYSE:BMY) has picked Onco360 to join the restricted specialty pharmacy network for ZENBEXUS (iberdomide). ZENBEXUS, a newly approved therapy for certain multiple myeloma patients, will be dispensed through a Risk Evaluation and Mitigation Strategy program. Onco360 will handle specialty dispensing and clinical support for eligible patients as ZENBEXUS enters commercial rollout for an underserved group. The selection of Onco360 for ZENBEXUS distribution comes against...
Top Stock Reports for Tesla, Bank of America & Coca-Cola
Tesla, Bank of America and Coca-Cola headline today's research, with growth drivers, investment plans and key risks in focus.
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
Leveraging Brazil's Health Networks for Early Lung Cancer Detection
Helen McGuire and Camilo Manchola discuss advancing lung cancer care by leveraging Brazil's existing tuberculosis platforms, proving the power of integrated, human-centered systems to stretch resources and improve patient outcomes.By Devex PartnershipsOriginally published on DevexNORTHAMPTON, MA / ACCESS Newswire / September 24, 2026 / In Brazil, lung cancer is a leading cause of cancer mortality, with approximately 85% of cases diagnosed at an advanced stage.
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
New Strong Buy Stocks for September 24th
BMY, HRTG, RDVT, NMR and ECO have been added to the Zacks Rank #1 (Strong Buy) List on September 24th, 2026.
Best Income Stocks to Buy for September 24th
ECO, NMR, BMY made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 24th, 2026.
Over $3.6M Raised to Build a More Connected Future of Mental Health at 32nd One Mind Music Festival Featuring The Fray
RUTHERFORD, Calif., September 23, 2026--On Saturday, September 19, 2026, leaders in science, philanthropy, and business, community members, and advocates gathered at the Staglin Family Vineyard in Napa Valley for the 32nd annual One Mind Music Festival, presented by Bank of America and Bristol Myers Squibb. The event welcomed more than 500 guests and raised over $3.6M to advance mental health research and discovery.
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP
The Rare Access Action Project (RAAP) announced today that Bristol Myers Squibb (BMS) has joined RAAP as its newest member, expanding the coalition of patient and life sciences stakeholders working together to address access and coverage challenges affecting people living with rare diseases.
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.
Eli Lilly Breaks Ground on $6.5B Generation Park Facility
A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization
BERLIN, September 22, 2026--AISB Network launches AISB Bind to improve prediction of how molecules bind for virtual screening and lead optimization
Transforming Lung Cancer Care & Early Detection in Tanzania
NORTHAMPTON, MA / ACCESS Newswire / September 22, 2026 / Originally published on DevexLung cancer remains the leading cause of cancer death worldwide, yet in resource-limited settings, patients face severe barriers to early diagnosis-while TB is regularly identified and treated, signs and indications of lung cancer are often overlooked. Nestory Masalu, Head of Oncology for the Catholic University of Health and Allied Sciences/Bugando Medical Center, explains how his team is dismantling these dia
Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network
LOUISVILLE, Ky., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a participating pharmacy by Bristol-Myers Squibb for ZENBEXUS™ (iberdomide), indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.¹ “Onco360 is grateful for the
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
What Would It Take For Pfizer To Cut Its Dividend?
Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder
The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.
Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
BMY vs. ARGX: Which Stock Is the Better Value Option?
BMY vs. ARGX: Which Stock Is the Better Value Option?
Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
Should Value Investors Buy Bristol Myers Squibb (BMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?
Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Bristol Myers Squibb (BMY) Funds India Lung Cancer Screening Research Beyond Smoking
Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The Bristol Myers Squibb Foundation is backing two clinical trials at the All India Institute of Medical Sciences in New Delhi. The projects aim to build localized lung cancer risk models and screening tools that include nonsmokers and people exposed to high air pollution. The Bristol Myers Squibb Foundation move into India focused lung cancer screening sits alongside wider...
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
PRINCETON, N.J., September 18, 2026--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
Bristol-Myers Squibb (BMY), What Is Behind The Fresh Attention?
Bristol-Myers Squibb (BMY) just paired new clinical data with income news, reporting positive two year Sotyktu results in psoriatic arthritis and affirming a quarterly dividend of US$0.63 per share for November payment. That mix of solid clinical data and a confirmed dividend comes as Bristol-Myers Squibb’s share price has climbed 16.37% over the past 90 days and 17.55% year to date, while the 1-year total shareholder return of 44.42% points to momentum that has been building rather than...
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
What Happens To AbbVie Stock If SKYRIZI Slows Down?
AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.
Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years
Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.
How Can Lung Cancer Screening in India Reflect Risk Beyond Smoking?
Opinion: Current lung cancer screening policy leaves gaps around air pollution, exposure, and genetics. Two new trials in India are creating the localized evidence needed to build a screening policy tailored to a true at-risk profile.
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
PRINCETON, N.J., September 17, 2026--Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Summit Therapeutics: It's Okay Not To Have An Answer
Summit Therapeutics' ivonescimab data looks promising but uncertain amid dilution, royalties and catalysts. See why I rate SMMT stock a Hold right now.
Bristol Myers Squibb Announces Two-Year Results From Its Phase 3 POETYK PSA-2 Study Showing Durable Efficacy And A Consistent Safety Profile For Sotyktu In Adults With Active Psoriatic Arthritis; Data Build On The Proven Efficacy And Safety Of Sotyktu
These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Huntington Beach, California, taking place September 17-20, 2026.Among patients who entered the OLE, Sotyktu demonstrated
Is Pfizer's New Business Big Enough To Carry The Old One?
Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.
AstraZeneca shares oversold after trial flops and merger talk, says UBS
UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker even after two clinical setbacks and speculation about a mega-merger. The stock has fallen roughly 15% since early July, when two...
Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82
Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J., September 16, 2026--Bristol Myers Squibb Announces Dividend
Merck Stock: Is The $70 Billion Pipeline Worth the Premium?
A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.
Can Redwire's Microgravity Platform Expand Commercial Opportunities?
RDW turns microgravity into a commercial platform, spanning pharmaceutical research, biotechnology and advanced manufacturing.
The Bull Case For Bristol Myers Squibb (BMY) Could Change Following Arlo-cel’s Positive Phase 2 Myeloma Data
In early September 2026, Bristol Myers Squibb reported positive Phase 2 results from its registrational QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel), a potential first-in-class GPRC5D-directed CAR T cell therapy for heavily pretreated adults with relapsed and refractory multiple myeloma, meeting its primary and key secondary response endpoints with a safety profile in line with existing CAR T treatments. The data are particularly important because arlo-cel targets GPRC5D...
Why Is Pfizer Stock Paying You So Much To Wait?
Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.
3 Healthcare Stocks That Fall Short
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.
Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
DelveInsight's Bispecifics Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis, Systemic Lupus Erythema
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
Cytokinetics, Incorporated stock faces pressure as Myqorzo sales jump 427% and NEJM Phase 3 data show efficacy vs. Camzyosâplus LVEF risk. Click for more on CYTK stock.
Big Pharma Is Pouring Billions Into China’s Biotechs
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?
As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.
How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?
Collecting $10,000 a year from Bristol Myers Squibb sounds straightforward until you factor in a looming patent cliff that threatens the very earnings funding that payout. Here is what the math and the risk actually look like together.
Is AbbVie Stock Actually Overpriced?
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline
Bristol-Myers Squibb Company (NYSE:BMY) said its experimental CAR-T cell therapy, arlocabtagene autoleucel (arlo-cel), met the main goal of a mid-stage trial in patients with advanced multiple myeloma who had already gone through four major classes of standard treatments. The therapy produced a statistically significant and clinically meaningful improvement in overall response rates. It also met […]
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More.
Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
‘Miracle’ Cancer Drug Sets Revolution Medicines Up for More Market Share Gains
Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
Cytokinetics (CYTK) likely has the upper hand in its patent dispute with Bristol-Myers Squibb (BMY)
Why Has AbbVie Gone Quiet About Humira?
AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.
HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65
HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.
Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question
BMY clears ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but high payout and falling earnings raise sustainability concerns.
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes
Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently […]
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For AllPreviously published by the Robert A. Winn Excellence in Clinical Trials Award ProgramA growing coalition of pharmaceutical companies, nonprofit organizations, academic institutions, and clinical research leaders came together through the Robert A.
Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair
PHILADELPHIA & BOSTON, September 09, 2026--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointments of Donald Hayden, M.B.A., as Chairman and Michael MacLean as independent director and Chair of the Audit Committee of the Latus Board of Directors. Mr. Hayden and Mr. MacLean bring decades of executive leadership experience in driving successful biopharmaceutical companies through key value inflection points and delivering advanced medi
SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
Potential extends to earlier-line use, injection-averse patients and new immune-mediated indicationsDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "SOTYKTU Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of SOTYKTU (deucravacitinib) across approved and potential immune-mediated inflammatory disease indications. The analysis covers the seven major markets (7MM): the United States, Germany, France,
Giovanni Caforio Appointed Operating Advisor to CD&R Funds
CD&R (or the "Firm") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating new investment opportunities within healthcare, as well as working with its portfolio companies globally.
A new immuno-oncology play raises $225M for a next-generation drug
Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
Is AbbVie Stock Too Reliant On Skyrizi?
AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.
Here’s How Much You Need Invested to Collect $1,000 a Month in Dividends
Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts every time prices move, and choosing the wrong yield can leave you exposed to a dividend cut when you can least afford it.
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.
What Merck Stopped Saying About GARDASIL Should Change What You Watch
Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.
Social Security’s 2027 COLA Raise Is the Biggest in 3 Years — But These 5 Dividend Stocks Pay You More
Social Security's projected 2027 COLA raise sounds promising until you realize retirees feel higher prices months before benefits catch up. Five blue-chip dividend stocks already pay yields that outpace that adjustment, and some have raised their payouts for decades straight.
Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients
Bristol Myers Squibb reported positive Phase 2 results for its arlo-cel therapy, meeting key endpoints for multiple myeloma patients.
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
PRINCETON, N.J., September 08, 2026--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial
Bristol Myers Squibb Reports Phase 2 Results From Registrational QUINTESSENTIAL Trial Of Arlocabtagene Autoleucel In Quadruple-Class Exposed RRMM Patients; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate
Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted therapyQUINTESSENTIAL
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for ATR 1072 and the launch of Corventis, its first Phase 1/2 trial and the first study anywhere testing a disease-modifying […]
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup
BMY shows a strong breakout setup: 10/10 technical rating, 9/10 setup score. Rising moving averages and a buy stop at $68.10 make it one to watch.
Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum
Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing valuation re-rating. Click for more on BMY.
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns
Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
Bristol Myers Squibb (BMY) stock: Strong Buy at 51% sector discount.
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price
Bristol Myers Squibb's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting total revenue growth. See why BMY stock is a Buy.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Samuels Theodore R. II | +821 | $62.4 | $51,230 |
| 2026-09-30 | McMullen Michael R. | +561 | $62.4 | $35,006 |
| 2026-09-30 | Rice Derica W | +621 | $62.4 | $38,750 |
| 2026-09-30 | Arduini Peter J | +561 | $62.4 | $35,006 |
| 2026-09-30 | YALE PHYLLIS R | +561 | $62.4 | $35,006 |
| 2026-09-09 | Massacesi Cristian | -6,249 | $64.57 | $403,498 |
| 2026-09-01 | Short Bartie Wendy | -1,236 | - | - |
| 2026-09-01 | Short Bartie Wendy | -633 | $66.92 | $42,360 |
| 2026-09-01 | Short Bartie Wendy | +1,236 | $66.92 | $82,713 |
| 2026-08-25 | Holzer Phil M | -500 | $67.5 | $33,750 |
| 2026-08-01 | Massacesi Cristian | -51,172 | - | - |
| 2026-08-01 | Massacesi Cristian | -26,175 | $65.31 | $1,709,489 |
| 2026-08-01 | Massacesi Cristian | +51,172 | - | - |
| 2026-08-01 | Gallman Cari | -1,061 | - | - |
| 2026-08-01 | Gallman Cari | -543 | $65.31 | $35,463 |
| 2026-08-01 | Gallman Cari | +1,061 | - | - |
| 2026-06-30 | Samuels Theodore R. II | +889 | $57.62 | $51,224 |
| 2026-06-30 | McMullen Michael R. | +607 | $57.62 | $34,975 |
| 2026-06-30 | Rice Derica W | +673 | $57.62 | $38,778 |
| 2026-06-30 | Arduini Peter J | +607 | $57.62 | $34,975 |
| 2026-06-30 | YALE PHYLLIS R | +607 | $57.62 | $34,975 |
| 2026-06-15 | Haller Julia A | -20,460 | - | - |
| 2026-06-15 | Haller Julia A | +20,460 | $53.76 | $1,099,930 |
| 2026-06-03 | Short Bartie Wendy | -8,040 | - | - |
| 2026-06-03 | Short Bartie Wendy | -3,876 | $54.72 | $212,095 |
| 2026-06-03 | Short Bartie Wendy | +8,040 | - | - |
| 2026-05-01 | Lenkowsky Adam | -1,373 | - | - |
| 2026-05-01 | Lenkowsky Adam | -599 | $58.22 | $34,874 |
| 2026-05-01 | Lenkowsky Adam | -203 | - | - |
| 2026-05-01 | Lenkowsky Adam | +1,373 | - | - |
| 2026-04-01 | Shanahan Karin | -3,307 | - | - |
| 2026-04-01 | Shanahan Karin | -1,692 | $61.73 | $104,447 |
| 2026-04-01 | Shanahan Karin | +3,307 | - | - |
| 2026-04-01 | Elkins David V | -4,481 | $62.05 | $278,046 |
| 2026-04-01 | Elkins David V | -25,519 | $61.6 | $1,571,970 |
| 2026-03-31 | Samuels Theodore R. II | +845 | $60.65 | $51,249 |
| 2026-03-31 | McMullen Michael R. | +577 | $60.65 | $34,995 |
| 2026-03-31 | Rice Derica W | +639 | $60.65 | $38,755 |
| 2026-03-31 | Arduini Peter J | +577 | $60.65 | $34,995 |
| 2026-03-31 | YALE PHYLLIS R | +577 | $60.65 | $34,995 |
| 2026-03-10 | Massacesi Cristian | +39,184 | - | - |
| 2026-03-10 | Massacesi Cristian | +26,122 | - | - |
| 2026-03-10 | Poole Ahn Amanda | +23,020 | - | - |
| 2026-03-10 | Poole Ahn Amanda | +15,347 | - | - |
| 2026-03-10 | Poole Ahn Amanda | -4,822 | - | - |
| 2026-03-10 | Poole Ahn Amanda | -803 | - | - |
| 2026-03-10 | Poole Ahn Amanda | -811 | - | - |
| 2026-03-10 | Poole Ahn Amanda | -1,256 | $60.13 | $75,523 |
| 2026-03-10 | Poole Ahn Amanda | -2,368 | - | - |
| 2026-03-10 | Poole Ahn Amanda | +4,822 | - | - |
| 2026-03-10 | Poole Ahn Amanda | -367 | $60.13 | $22,068 |
| 2026-03-10 | Poole Ahn Amanda | -87 | - | - |
| 2026-03-10 | Poole Ahn Amanda | +803 | - | - |
| 2026-03-10 | Poole Ahn Amanda | -369 | $60.13 | $22,188 |
| 2026-03-10 | Poole Ahn Amanda | -91 | - | - |
| 2026-03-10 | Poole Ahn Amanda | +811 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | +156,735 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | +104,490 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -17,788 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -40,398 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -6,733 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -6,618 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -4,632 | $60.13 | $278,522 |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -8,734 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | +17,788 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -10,518 | $60.13 | $632,447 |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -19,835 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | +40,398 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -3,073 | $60.13 | $184,779 |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -727 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | +6,733 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -3,006 | $60.13 | $180,751 |
| 2026-03-10 | BOERNER CHRISTOPHER S. | -743 | - | - |
| 2026-03-10 | BOERNER CHRISTOPHER S. | +6,618 | - | - |
| 2026-03-10 | Shibutani Hiroshi Chris | +11,755 | - | - |
| 2026-03-10 | Shibutani Hiroshi Chris | +7,837 | - | - |
| 2026-03-10 | Short Bartie Wendy | +9,796 | - | - |
| 2026-03-10 | Short Bartie Wendy | +6,531 | - | - |
| 2026-03-10 | Short Bartie Wendy | -4,495 | - | - |
| 2026-03-10 | Short Bartie Wendy | -749 | - | - |
| 2026-03-10 | Short Bartie Wendy | -639 | - | - |
| 2026-03-10 | Short Bartie Wendy | -828 | $60.13 | $49,788 |
| 2026-03-10 | Short Bartie Wendy | -2,207 | - | - |
| 2026-03-10 | Short Bartie Wendy | +4,495 | - | - |
| 2026-03-10 | Short Bartie Wendy | -242 | $60.13 | $14,551 |
| 2026-03-10 | Short Bartie Wendy | -81 | - | - |
| 2026-03-10 | Short Bartie Wendy | +749 | - | - |
| 2026-03-10 | Short Bartie Wendy | -205 | $60.13 | $12,327 |
| 2026-03-10 | Short Bartie Wendy | -72 | - | - |
| 2026-03-10 | Short Bartie Wendy | +639 | - | - |
| 2026-03-10 | Holzer Phil M | +7,547 | - | - |
| 2026-03-10 | Holzer Phil M | +5,031 | - | - |
| 2026-03-10 | Holzer Phil M | -4,612 | - | - |
| 2026-03-10 | Holzer Phil M | -768 | - | - |
| 2026-03-10 | Holzer Phil M | -811 | - | - |
| 2026-03-10 | Holzer Phil M | -849 | $60.13 | $51,050 |
| 2026-03-10 | Holzer Phil M | -2,264 | - | - |
| 2026-03-10 | Holzer Phil M | +4,612 | - | - |
| 2026-03-10 | Holzer Phil M | -248 | $60.13 | $14,912 |
| 2026-03-10 | Holzer Phil M | -83 | - | - |
| 2026-03-10 | Holzer Phil M | +768 | - | - |
| 2026-03-10 | Holzer Phil M | -261 | $60.13 | $15,694 |
| 2026-03-10 | Holzer Phil M | -91 | - | - |
| 2026-03-10 | Holzer Phil M | +811 | - | - |
| 2026-03-10 | Hoch Lynelle | +9,796 | - | - |
| 2026-03-10 | Hoch Lynelle | +6,531 | - | - |
| 2026-03-10 | Hoch Lynelle | -6,304 | - | - |
| 2026-03-10 | Hoch Lynelle | -1,050 | - | - |
| 2026-03-10 | Hoch Lynelle | -838 | - | - |
| 2026-03-10 | Hoch Lynelle | -912 | $60.13 | $54,839 |
| 2026-03-10 | Hoch Lynelle | -3,095 | - | - |
| 2026-03-10 | Hoch Lynelle | +6,304 | - | - |
| 2026-03-10 | Hoch Lynelle | -267 | $60.13 | $16,055 |
| 2026-03-10 | Hoch Lynelle | -113 | - | - |
| 2026-03-10 | Hoch Lynelle | +1,050 | - | - |
| 2026-03-10 | Hoch Lynelle | -212 | $60.13 | $12,748 |
| 2026-03-10 | Hoch Lynelle | -94 | - | - |
| 2026-03-10 | Hoch Lynelle | +838 | - | - |
| 2026-03-10 | Gallman Cari | +39,184 | - | - |
| 2026-03-10 | Gallman Cari | +26,122 | - | - |
| 2026-03-10 | Gallman Cari | -5,201 | - | - |
| 2026-03-10 | Gallman Cari | -867 | - | - |
| 2026-03-10 | Gallman Cari | -912 | - | - |
| 2026-03-10 | Gallman Cari | -1,354 | $60.13 | $81,416 |
| 2026-03-10 | Gallman Cari | -2,554 | - | - |
| 2026-03-10 | Gallman Cari | +5,201 | - | - |
| 2026-03-10 | Gallman Cari | -396 | $60.13 | $23,811 |
| 2026-03-10 | Gallman Cari | -94 | - | - |
| 2026-03-10 | Gallman Cari | +867 | - | - |
| 2026-03-10 | Gallman Cari | -415 | $60.13 | $24,954 |
| 2026-03-10 | Gallman Cari | -102 | - | - |
| 2026-03-10 | Gallman Cari | +912 | - | - |
| 2026-03-10 | Lenkowsky Adam | +48,980 | - | - |
| 2026-03-10 | Lenkowsky Adam | +32,653 | - | - |
| 2026-03-10 | Lenkowsky Adam | -8,241 | - | - |
| 2026-03-10 | Lenkowsky Adam | -12,002 | - | - |
| 2026-03-10 | Lenkowsky Adam | -2,000 | - | - |
| 2026-03-10 | Lenkowsky Adam | -1,828 | - | - |
| 2026-03-10 | Lenkowsky Adam | -2,146 | $60.13 | $129,039 |
| 2026-03-10 | Lenkowsky Adam | -4,046 | - | - |
| 2026-03-10 | Lenkowsky Adam | +8,241 | - | - |
| 2026-03-10 | Lenkowsky Adam | -3,125 | $60.13 | $187,906 |
| 2026-03-10 | Lenkowsky Adam | -5,893 | - | - |
| 2026-03-10 | Lenkowsky Adam | +12,002 | - | - |
| 2026-03-10 | Lenkowsky Adam | -913 | $60.13 | $54,899 |
| 2026-03-10 | Lenkowsky Adam | -216 | - | - |
| 2026-03-10 | Lenkowsky Adam | +2,000 | - | - |
| 2026-03-10 | Lenkowsky Adam | -831 | $60.13 | $49,968 |
| 2026-03-10 | Lenkowsky Adam | -205 | - | - |
| 2026-03-10 | Lenkowsky Adam | +1,828 | - | - |
| 2026-03-10 | Shanahan Karin | +31,837 | - | - |
| 2026-03-10 | Shanahan Karin | +21,224 | - | - |
| 2026-03-10 | Shanahan Karin | -19,760 | - | - |
| 2026-03-10 | Shanahan Karin | -3,293 | - | - |
| 2026-03-10 | Shanahan Karin | -2,448 | - | - |
| 2026-03-10 | Shanahan Karin | -5,145 | $60.13 | $309,369 |
| 2026-03-10 | Shanahan Karin | -9,702 | - | - |
| 2026-03-10 | Shanahan Karin | +19,760 | - | - |
| 2026-03-10 | Shanahan Karin | -1,503 | $60.13 | $90,375 |
| 2026-03-10 | Shanahan Karin | -356 | - | - |
| 2026-03-10 | Shanahan Karin | +3,293 | - | - |
| 2026-03-10 | Shanahan Karin | -1,112 | $60.13 | $66,865 |
| 2026-03-10 | Shanahan Karin | -275 | - | - |
| 2026-03-10 | Shanahan Karin | +2,448 | - | - |
| 2026-03-10 | Meyers Gregory Scott | +39,184 | - | - |
| 2026-03-10 | Meyers Gregory Scott | +26,122 | - | - |
| 2026-03-10 | Meyers Gregory Scott | -19,760 | - | - |
| 2026-03-10 | Meyers Gregory Scott | -3,293 | - | - |
| 2026-03-10 | Meyers Gregory Scott | -2,839 | - | - |
| 2026-03-10 | Meyers Gregory Scott | -4,267 | $60.13 | $256,575 |
| 2026-03-10 | Meyers Gregory Scott | -9,702 | - | - |
| 2026-03-10 | Meyers Gregory Scott | +19,760 | - | - |
| 2026-03-10 | Meyers Gregory Scott | -1,246 | $60.13 | $74,922 |
| 2026-03-10 | Meyers Gregory Scott | -356 | - | - |
| 2026-03-10 | Meyers Gregory Scott | +3,293 | - | - |
| 2026-03-10 | Meyers Gregory Scott | -1,069 | $60.13 | $64,279 |
| 2026-03-10 | Meyers Gregory Scott | -319 | - | - |
| 2026-03-10 | Meyers Gregory Scott | +2,839 | - | - |
| 2026-03-10 | Plenge Robert M | +26,939 | - | - |
| 2026-03-10 | Plenge Robert M | +17,959 | - | - |
| 2026-03-10 | Plenge Robert M | -14,052 | - | - |
| 2026-03-10 | Plenge Robert M | -2,342 | - | - |
| 2026-03-10 | Plenge Robert M | -1,107 | - | - |
| 2026-03-10 | Plenge Robert M | -3,172 | $60.13 | $190,732 |
| 2026-03-10 | Plenge Robert M | -6,900 | - | - |
| 2026-03-10 | Plenge Robert M | +14,052 | - | - |
| 2026-03-10 | Plenge Robert M | -927 | $60.13 | $55,741 |
| 2026-03-10 | Plenge Robert M | -253 | - | - |
| 2026-03-10 | Plenge Robert M | +2,342 | - | - |
| 2026-03-10 | Plenge Robert M | -436 | $60.13 | $26,217 |
| 2026-03-10 | Plenge Robert M | -124 | - | - |
| 2026-03-10 | Plenge Robert M | +1,107 | - | - |
| 2026-03-10 | Hickey Benjamin | +17,143 | - | - |
| 2026-03-10 | Hickey Benjamin | +11,429 | - | - |
| 2026-03-10 | Elkins David V | +52,898 | - | - |
| 2026-03-10 | Elkins David V | +35,265 | - | - |
| 2026-03-10 | Elkins David V | -47,424 | - | - |
| 2026-03-10 | Elkins David V | -7,904 | - | - |
| 2026-03-10 | Elkins David V | -7,654 | - | - |
| 2026-03-10 | Elkins David V | -10,240 | $60.13 | $615,731 |
| 2026-03-10 | Elkins David V | -23,285 | - | - |
| 2026-03-10 | Elkins David V | +47,424 | - | - |
| 2026-03-10 | Elkins David V | -2,991 | $60.13 | $179,849 |
| 2026-03-10 | Elkins David V | -854 | - | - |
| 2026-03-10 | Elkins David V | +7,904 | - | - |
| 2026-03-10 | Elkins David V | -2,883 | $60.13 | $173,355 |
| 2026-03-10 | Elkins David V | -860 | - | - |
| 2026-03-10 | Elkins David V | +7,654 | - | - |
| 2026-02-27 | Hickey Benjamin | -3,286 | - | - |
| 2026-02-27 | Hickey Benjamin | -1,672 | $62.37 | $104,283 |
| 2026-02-27 | Hickey Benjamin | +3,286 | - | - |
| 2026-02-01 | Bhatt Deepak | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | Meyers Gregory Scott | -2,543 | - | - |
| 2026-02-01 | Meyers Gregory Scott | -833 | $55.05 | $45,857 |
| 2026-02-01 | Meyers Gregory Scott | +2,543 | - | - |
| 2026-02-01 | Hidalgo Medina Manuel | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | Hickey Benjamin | -10,079 | - | - |
| 2026-02-01 | Hickey Benjamin | -3,810 | $55.05 | $209,741 |
| 2026-02-01 | Hickey Benjamin | +10,079 | - | - |
| 2026-02-01 | Vousden Karen H | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | Samuels Theodore R. II | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | Haller Julia A | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | McMullen Michael R. | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | Price Paula A | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | Rice Derica W | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | Arduini Peter J | +3,996 | $55.05 | $219,980 |
| 2026-02-01 | YALE PHYLLIS R | +3,996 | $55.05 | $219,980 |
| 2025-12-31 | Samuels Theodore R. II | +927 | - | - |
| 2025-12-31 | McMullen Michael R. | +649 | - | - |
| 2025-12-31 | Rice Derica W | +695 | - | - |
| 2025-12-31 | Arduini Peter J | +626 | - | - |
| 2025-12-31 | YALE PHYLLIS R | +649 | - | - |
| 2025-11-03 | Lenkowsky Adam | +22,568 | - | - |
| 2025-11-01 | Shanahan Karin | -6,281 | - | - |
| 2025-11-01 | Shanahan Karin | -3,213 | $46.07 | $148,023 |
| 2025-11-01 | Shanahan Karin | +6,281 | - | - |
| 2025-11-01 | Meyers Gregory Scott | -6,281 | - | - |
| 2025-11-01 | Meyers Gregory Scott | -2,665 | $46.07 | $122,777 |
| 2025-11-01 | Meyers Gregory Scott | +6,281 | - | - |
| 2025-11-01 | BOERNER CHRISTOPHER S. | -2,964 | - | - |
| 2025-11-01 | BOERNER CHRISTOPHER S. | -1,238 | $46.07 | $57,035 |
| 2025-11-01 | BOERNER CHRISTOPHER S. | -544 | - | - |
| 2025-11-01 | BOERNER CHRISTOPHER S. | +2,964 | - | - |